首页> 美国卫生研究院文献>other >Impact of Disease Progression Date Determination on Progression-free Survival Estimates in Advanced Lung Cancer

【2h】

Impact of Disease Progression Date Determination on Progression-free Survival Estimates in Advanced Lung Cancer

机译：疾病进展日期确定对无进展生存期影响的估计中晚期肺癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PURPOSEProgression-free survival (PFS) based endpoints are controversial; however in advanced lung cancer, overall survival is largely influenced by the progression status. We thus evaluated the impact of progression date (PD) determination approach on PFS estimates.

机译：无意的自由生存（PFS）的终点是有争议的;然而，在晚期的肺癌中，整体存活率在很大程度上受到进展状况的影响。因此，我们评估了进展日期（PD）确定方法对PFS估计的影响。

著录项

期刊名称 other
作者
Yingwei Qi; Allen Ziegler; L. Katie; Shauna L. Hillman; Mary W. Redman; Steven E. Schild; David R. Gandara; Alex A. Adjei; Sumithra J. Mandrekar;
展开▼
作者单位

展开▼
年(卷),期 -1(118),21
年度 -1
页码 5358–5365
总页数 12
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer [J] . QiY., AllenZieglerK.L., HillmanS.L., Cancer: A Journal of the American Cancer Society . 2012,第21期

机译：疾病进展日期确定对晚期肺癌无进展生存期估计的影响
2. Long progression-free survival with first-line paditaid_. pies platinum is associated with Improved response and progression-free survival with second-line docetaxel In advanced non-small-cell lung cancer [J] . Eleazar Omar Macedo-Perez, Vicente Morales-Oyarvide, Victor Osvaldo Mendoza-Garcia, Cancer chemotherapy and pharmacology. . 2014,第4期

机译：一线paditaid_可长期无进展生存。派斯铂与二线多西紫杉醇改善晚期非小细胞肺癌的应答和无进展生存相关
3. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-Part 2) [J] . CadranelJ., MauguenA., FallerM., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012,第10期

机译：在法国前瞻性队列研究中，系统性的EGFR和KRAS突变评估对厄洛替尼治疗的晚期非小细胞肺癌患者无进展生存和总体生存的影响（ERMETIC项目第2部分）
4. Development and validation of a radiomics nomogram for progression-free survival prediction in stage IV EGFR-mutant non-small cell lung cancer [C] . Jiangdian Song, Yali Zang, Weimin Li, Conference on Computer-Aided Diagnosis . 2017

机译：放射组学诺模图的开发和验证，用于IV期EGFR突变非小细胞肺癌的无进展生存期预测
5. Statistical Models to Capture the Association Between Progression-Free and Overall Survival in Oncology Trials [D] . Weber, Enya Maria. 2020

机译：统计模型捕获肿瘤学试验无进展和整体生存之间的关联
6. PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response Progression-Free Survival and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors [O] . Foteinos-Ioannis Dimitrakopoulos, Achilleas Nikolakopoulos, Anastasia Kottorou, 2020

机译：PIOS（Patras免疫治疗评分）评分与接受抗程序性细胞死亡1（PD）治疗的晚期非小细胞肺癌（NSCLC）患者的最佳总体缓解率无进展生存期和免疫治疗后总体生存率相关-1）抑制剂
7. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-Part 2) [O] . Cadranel, Jacques, Mauguen, Audrey, Faller, Michele M., 2012

机译：在法国前瞻性队列研究中，系统性的EGFR和KRAS突变评估对厄洛替尼治疗的晚期非小细胞肺癌患者无进展生存和总体生存的影响（ERMETIC项目第2部分）

Impact of Disease Progression Date Determination on Progression-free Survival Estimates in Advanced Lung Cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅